Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Kisqali
(United States) [Available]Synonyms :
ribociclib
Class :
Antineoplastic agents and CDK Inhibitors; Aromatase Inhibitors
Brand Name :
Kisqali
(United States) [Available]Synonyms :
ribociclib
Class :
Antineoplastic agents and CDK Inhibitors; Aromatase Inhibitors
ribociclib is indicated in women with (HR)-positive hormone receptor (HER2) human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
A dose of 600 mg is administered each day orally for the initial 21 days of every 28-day cycle
The medication is continued until the disease is reduced to acceptable toxicity
Dose Adjustments
In case of adverse reactions, the dose is modified or reduced
The pattern of dose reduction goes like this
First dose reduction: 400 mg daily
Second dose reduction: 200 mg daily
In case the patient is unable to tolerate 200 mg daily, discontinue the treatment
Hepatic impairment
In the case of mild Child-Pugh A, there is no dose adjustment required
In case of moderate-to-severe Child-Pugh B or C: Reduce the starting dose to 400 mg/day
Renal impairment
In the case of mild-to-moderate (CrCl ≥30 mL/min): No dose adjustment is necessary
In case of severe (CrCl 15-30 mL/min): reduce the starting dose to 200 mg/day
may enhance the serum concentration of CYP3A4 inhibitors
it enhances the immunosuppressant activity of immunosuppressants
CYP3A4 inhibitors increase the concentration of aprepitant in serum
it enhances the immunosuppressant activity of baricitinib
CYP3A4 inhibitors increase the concentration of bosutinib in serum
it enhances the myelosuppressive activity of cladribine
they decrease the concentration of ribociclib in serum
CYP3A4 inhibitors increase the concentration of eletriptan in serum
it increases the concentration of CYP3A4 substrates in serum
it increases the concentration of ivabradine in serum
it increases the concentration of lonafarnib in serum
it increases the concentration of nisoldipine in serum
it increases the concentration of ribociclib in serum
CYP3A4 inhibitors increase the concentration of simeprevir in serum
immunosuppressants decrease the activity of tertomotide
immunosuppressants increase the immunosuppressive activity of upadacitinib
vaccines: immunosuppressants decrease the efficacy of vaccines
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
both lapatinib and ribociclib increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ribociclib
CYP3A4 inhibitors increase the concentration of abemaciclib in serum
CYP3A4 inhibitors increase the concentration of amlodipine in serum
CYP3A4 inhibitors increase the concentration of bortezomib in serum
CYP3A4 inhibitors increase the concentration of cabozantinib in serum
CYP3A4 inhibitors increase the concentration of copanlisib in serum
CYP3A4 inhibitors increase the concentration of dabrafenib in serum
CYP3A4 inhibitors increase the concentration of ebastine in serum
CYP3A4 inhibitors increase the concentration of fosamprenavir in serum
CYP3A4 inhibitors decrease the concentration of active metabolites of ifosfamide in serum
CYP3A4 inhibitors increase the concentration of larotrectinib in serum
CYP3A4 inhibitors increase the concentration of manidipine in serum
CYP3A4 inhibitors increase the concentration of naldemedine in serum
CYP3A4 inhibitors increase the concentration of oliceridine in serum
CYP3A4 inhibitors increase the concentration of pimavanserin in serum
CYP3A4 inhibitors increase the concentration of ranolazine in serum
CYP3A4 inhibitors increase the concentration of sildenafil in serum
CYP3A4 inhibitors increase the concentration of tamsulosin in serum
CYP3A4 inhibitors increase the concentration of zopiclone in serum
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance the effects when combined with tasimelteon by affecting CYP3A4 metabolism
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be a reduced metabolism of erlotinib
may increase the serum concentration and toxic effects of tamoxifen
the effect of ribociclib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolismlorl
it decreases the concentration of tamoxifen in serum
Inhibits the CYP3A4 metabolism of busulfan and increases the effect.
ribociclib increases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
it increases the effect or level of osimertinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
it increases by affecting the hepatic enzyme CYP3A4 metabolism
The selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6 is ribociclib. Binding to D-cyclins activates these kinases, which are downstream of signaling pathways that promote cell proliferation and cell cycle advancement.
The cyclin D-CDK4/6 complex phosphorylates the retinoblastoma protein (pRb) to control the advancement of the cell cycle.
In models derived from breast cancer, ribociclib has been demonstrated to diminish pRb phosphorylation, which leads to cell cycle arrest in the G1 phase and decreased proliferation.
Frequency defined:
>10%
Leukocyte count decreased
Neutrophil count decreased
Neutropenia
Hemoglobin decreased
Nausea
Lymphocyte count decreased
Neutropenia
Neutrophil count decreased
AST/ALT increased
Fatigue
Diarrhea
Leukopenia
Alopecia
Leukocyte count decreased
Platelets decreased
Vomiting
Headache
Leukopenia
Back pain
Creatinine increased
Decreased appetite
Anemia
Abnormal LFTs
Rash
Pruritus
Pyrexia
Phosphorus decreased
Peripheral edema
Stomatitis
Insomnia
Dyspnea
Lymphopenia
Urinary tract infection
Abdominal pain
Potassium decreased
1-10%
Neutropenia
None
Contraindication:
None
Caution:
Interstitial lung disease/pneumonitis
Severe cutaneous adverse reactions
Hepatotoxicity
Neutropenia
Pregnancy consideration: The drug is toxic and unsafe for pregnant women and the developing fetus.
Breastfeeding warnings: No data on the excretion of ribociclib in breast milk is available. Because of possible serious effects, women are advised to breastfeed three weeks after the last dose of ribociclib.
Pregnancy category:
The QTcF interval varies with concentration when using ribociclib. Patients receiving other QTc-prolonging medications should use it with caution.
A reduction in the number of tumor cells is associated with the inhibition of pRb phosphorylation.
These kinases are essential for signalling pathways that bring about cell cycle progression and cellular proliferation, and they are active when they bind to D cyclins.
Letrozole and ribociclib should be taken daily at roughly the same time in the morning.
It is taken orally in tablet form with or without food.
Take in the morning or the evening at the same time every day. It should be swallow as whole at time.
If a tablet is cracked, fractured, or otherwise unusable, it should not be taken.
If you miss a dose or throw up, you should not take any more that day. Instead, take the next dose at your regular time.
Patient information leaflet
Generic Name: ribociclib
Why do we use ribociclib?
Adults at high risk of recurrence with stage II and III early breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative can benefit from adjuvant treatment with ribociclib in combination with an aromatase inhibitor.
It is also recommended for people with HR-positive, HER2-negative advanced or metastatic breast cancer when taken in combination with an aromatase inhibitor or fulvestrant.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
